Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman Sells 1,767 Shares

Natera, Inc. (NASDAQ:NTRA) Director Rowan E. Chapman sold 1,767 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $170.24, for a total transaction of $300,814.08. Following the sale, the director now directly owns 6,202 shares of the company’s stock, valued at approximately $1,055,828.48. This represents a 22.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Natera Stock Up 0.1 %

NASDAQ NTRA opened at $166.55 on Friday. Natera, Inc. has a 1-year low of $57.22 and a 1-year high of $175.63. The company has a market capitalization of $21.99 billion, a price-to-earnings ratio of -94.63 and a beta of 1.63. The stock’s 50 day moving average is $144.02 and its two-hundred day moving average is $124.46. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same quarter in the previous year, the firm earned ($0.95) EPS. Natera’s quarterly revenue was up 63.9% on a year-over-year basis. Equities analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several large investors have recently made changes to their positions in NTRA. Farallon Capital Management LLC boosted its position in Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after buying an additional 532,874 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after acquiring an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock worth $315,194,000 after acquiring an additional 85,236 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Natera by 7.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock worth $265,747,000 after acquiring an additional 143,825 shares in the last quarter. Finally, Duquesne Family Office LLC grew its position in Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after acquiring an additional 45,500 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NTRA. Canaccord Genuity Group boosted their target price on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Sanford C. Bernstein boosted their price objective on Natera from $125.00 to $135.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. TD Cowen raised their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Piper Sandler raised their price objective on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Finally, The Goldman Sachs Group boosted their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $147.50.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.